» Home » Drug Database » Antiarrhythmic Drugs » mibefradil
ADVERTISEMENT
ADVERTISEMENT
» Home » Drug Database » Antiarrhythmic Drugs » mibefradil
Brand Name :
Posicor
(United States) [DSC]| country | status | Month | Year |
|---|
Synonyms :
mibefradil
Class :
Calcium Antagonists
Actions and Spectrum:
Action: mibefradil selectively blocks T-type calcium channels in the heart and peripheral blood vessels. Doing so reduces the influx of calcium ions into these cells, leading to vasodilation (widening of blood vessels) and decreased cardiac contractility. The net effect is a reduction in blood pressure and a decrease in the workload on the heart, making it an effective antihypertensive and antianginal agent.
Spectrum: mibefradil was initially approved to treat hypertension and chronic stable angina. Its unique mechanism of action, particularly its inhibition of T-type calcium channels, made it a promising alternative to other calcium channel blockers.
No drug interaction found for mibefradil and .
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may increase the hypotensive effect of alpha1-blockers
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
may enhance the serum concentration of each other when combined
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
CYP3A Inhibitors: they may diminish the serum concentration of hormonal agents
QT-prolonging Strong may enhance the QTc-prolonging effect of delamanid
dasatinib may enhance the QTc-prolonging effect of QT-prolonging
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
may decrease the serum concentration of Quinolones
bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib
bradycardia-Causing Agents may enhance the bradycardic effect of ponesimod
may enhance the QTc-prolonging effect of Fluorouracil Products
gilteritinib may enhance the QTc-prolonging effect of QT-prolonging Agents
may increase the serum concentration of colchicine
may enhance the Qtc prolonging effect
may increase the levels of serum concentration of ivacaftor/tezacaftor
may enhance the serum concentrations of active metabolites
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the serum concentration
may increase the serum concentration
may increase the QTc prolonging effect
may increase the QTc prolonging effect
may increase the hypotensive effect of anti-hypertensive agents
may increase the hypotensive effect of anti-hypertensive agents
may increase the bradycardic effect of bradycardia-causing agents
may enhance serum concentrations when combined with tetrabenazine
may increase the level of serum concentration of adagrasib
may enhance the serum concentration when combined with fenfluramine
may enhance the serum concentration when combined with fenfluramine
may diminish the serum concentration when combined with CYP2D6 substrates
may have an increased QTc-prolonging effect when combined with amisulpride (oral)
may decrease the therapeutic effect of each other when combined
may enhance the serum concentration
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may increase the QTc prolonging effect of QT-prolonging agents
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may increase the serum concentration of Rasagiline
may have an increased QTc-prolonging effect when combined with amiodarone
may have an increased QTc-prolonging effect when combined with arsenic trioxide
may have an increased QTc-prolonging effect when combined with astemizole
may have an increased QTc-prolonging effect when combined with bedaquiline
may have an increased QTc-prolonging effect when combined with chloroquine
may have an increased QTc-prolonging effect when combined with chlorpromazine
may have an increased QTc-prolonging effect when combined with cisapride
may have an increased QTc-prolonging effect when combined with clofazimine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with clozapine
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with dasatinib
may have an increased QTc-prolonging effect when combined with delamanid
may have an increased QTc-prolonging effect when combined with doxepin-containing products
may increase the QTc-prolonging effect of QT-prolonging Agents
may have an increased bradycardic effect when combined with ceritinib
may have an increased bradycardic effect when combined with fingolimod
may have an increased bradycardic effect when combined with ponesimod
may have an increased bradycardic effect when combined with siponimod
may enhance the concentration of serum when combined with theophylline derivatives
may diminish the serum concentration of Voxelotor
may enhance the concentration of serum when combined with thioridazine
lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors
pirfenidone: they may enhance the serum concentration of CYP1A2 Inhibitors
pomalidomide: they may enhance the serum concentration of CYP1A2 Inhibitors
propranolol: they may enhance the serum concentration of CYP1A2 Inhibitors
sirolimus: they may enhance the serum concentration of CYP3A4 Inhibitors
budesonide: they may enhance the serum concentration of CYP3A4 Inhibitors
may increase the QTc-prolonging effect of each other when combined
May enhance the QTc-prolonging effect of each other when combined
dronedarone: they may increase the QTc-prolonging effect of QTc-prolonging miscellaneous agents
encorafenib: they may increase the QTc-prolonging effect of QTc-prolonging agents
escitalopram: they may increase the QTc-prolonging effect of QTc-prolonging Agents
etelcalcetide: they may increase the QTc-prolonging effect of QTc-prolonging agents
flecainide: they may increase the QTc-prolonging effect of QTc-prolonging Agents
fluconazole: they may increase the QTc-prolonging effect of QTc-prolonging agents
gilteritinib: they may increase the QTc-prolonging effect of QTc-prolonging agents
halofantrine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
imipramine: they may increase the QTc-prolonging effect of QTc-prolonging agents
inotuzumab: they may enhance the QTc-prolonging effect of QTc-prolonging agents
may increase the hypotensive effect of anti-hypertensive agents
lofexidine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
midostaurin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
olanzapine: they may enhance the QTc-prolonging effect of QTc-prolonging Agents
osimertinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propafenone: they may increase the QTc-prolonging effect of QTc-prolonging Agents
propofol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sunitinib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
toremifene: they may increase the QTc-prolonging effect of QTc-prolonging Agents
vemurafenib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
may enhance the QTc-prolonging effect of each other when combined
alfentanil: they may enhance the serum concentration of CYP3A Inhibitors
avanafil: they may enhance the serum concentration of CYP3A Inhibitors
budesonide: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cisapride: they may enhance the serum concentration of CYP3A Inhibitors
dapoxetine: they may enhance the serum concentration of CYP3A Inhibitors
daridorexant: they may enhance the serum concentration of CYP3A Inhibitors
eliglustat: they may enhance the serum concentration of CYP3A Inhibitors
encorafenib: they may enhance the serum concentration of CYP3A Inhibitors
eplerenone: they may enhance the serum concentration of CYP3A Inhibitors
fentanyl: they may enhance the serum concentration of CYP3A Inhibitors
ivacaftor: they may enhance the serum concentration of CYP3A Inhibitors
lumateperone: they may enhance the serum concentration of CYP3A Inhibitors
mitapivat: they may enhance the serum concentration of CYP3A Inhibitors
naloxegol: they may enhance the serum concentration of CYP3A Inhibitors
may enhance the antihypertensive effect of other alpha1-Blockers
bunazosin (Not available in the United States)
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
may enhance the antihypertensive effect of other alpha1-Blockers
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
it may enhance the QTc-prolonging effect of terfenadine
may enhance the QTc-prolonging effect of Nilotinib
it decreases the effect of hypotension on blood-lowering agents
CYP2D6 inhibitors increase the concentration of aripiprazole in the serum
they decrease the concentration of active metabolites of roflumilast in the serum
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in serum
may increase the levels of serum concentration of eletriptan
they increase the concentration of alosetron in the serum
bradycardia causing agents increase the arrhythmia-causing effect of fexinidazole
may increase the Qtc prolonging effect
may enhance the serum concentration
may increase the hypotensive effect of anti-hypertensive agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
QTc-prolongers increase the effect of other QTc-prolonging agents
may have an increased hyperkalemic effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
bunazosin (Not available in the United States)
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
may have an increased hypotensive effect when combined with calcium channel blockers
they decrease the concentration of active metabolites of infigratinib in the serum
CYP3A4 inhibitors increase the concentration of pimozide in the serum
they decrease the concentration of active metabolites of iloperidone in the serum
may enhance the serum concentration of tafamidis
May enhance the hyperkalemic effect when combined with Calcium Channel Blockers
may have an increased QTc-prolonging effect when combined with citalopram
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with flupentixol
may have an increased QTc-prolonging effect when combined with nilotinib
may have an increased QTc-prolonging effect when combined with pazopanib
may enhance the serum concentration when combined
may decrease the therapeutic effect when combined with etofylline
they decrease the concentration of lurbinectedin in the serum
QT-prolonging agents (Highest Risk) may increase clarithromycin's ability to prolong QTc
May increase the QTc-prolonging effect of QT-prolonging Agents
may increase the QTc-prolonging effect of QT-prolonging Agents
may diminish the concentration of serum when combined with CYP1A2 substrates
agomelatine: they may enhance the serum concentration of CYP1A2 Inhibitors
duloxetine: they may enhance the serum concentration of CYP1A2 Inhibitors
melatonin: they may enhance the serum concentration of CYP1A2 Inhibitors
mexiletine: they may enhance the serum concentration of CYP1A2 Inhibitors
ramelteon: they may enhance the serum concentration of CYP1A2 Inhibitors
tasimelteon: they may enhance the serum concentration of CYP1A2 Inhibitors
thiazide and it’s like diuretics increase the effect of QTc prolongation
May enhance the QTc-prolonging effect of QT-prolonging Class IA Antiarrhythmics
may increase the serum concentration of each other when combined
may increase the hypertensive effect when combined with androgens
piperaquine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
probucol: they may increase the QTc-prolonging effect of QTc-prolonging Agents
quetiapine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
ribociclib: they may increase the QTc-prolonging effect of QTc-prolonging Agents
sparfloxacin: they may increase the QTc-prolonging effect of QTc-prolonging Agents
thioridazine: they may increase the QTc-prolonging effect of QTc-prolonging Agents
fexinidazole: they may enhance the serum concentration of CYP3A4 inhibitors
fusidic acid: they may enhance the serum concentration of CYP3A inhibitors
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
may increase the QTc-prolonging effect of each other when combined
trabectedin: they may diminish the serum concentration of CYP3A Inhibitors
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
it may enhance the QTc-prolonging effect of QT-Prolonging Anesthetics
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of Quinolone antibiotics
may enhance the hypotensive effect of calcium channel blockers
bunazosin (Not available in the United States)
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the hypotensive effect of calcium channel blockers
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may enhance the AV-blocking effect of cardiac glycosides
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
they increase the QTc prolongation effect of other QT-prolonging agents
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
bazedoxifene/conjugated estrogens
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
synthetic conjugated estrogens, a
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
synthetic conjugated estrogens, b
CYP3A4 inhibitors (Strong) may increase the serum concentration of estrogen related drugs
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of neuromuscular-blocking agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may enhance the effect of antipsychotic agents
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may increase the serum concentration of ergot derivatives
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the effect of other bradycardia agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the QTc-prolonging effect of other QT-prolonging Agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may enhance the hypotensive effect of antipsychotic agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
they increase the risk of other QT prolongers
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of estrogen derivatives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may increase the levels of serum concentration of hormonal contraceptives
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
relugolix/estradiol/norethindrone
may enhance the hypertensive effect of Androgens
relugolix/estradiol/norethindrone
may enhance the hypertensive effect of Androgens
may enhance the hypertensive effect of Androgens
may enhance the hypertensive effect of Androgens
may enhance the hypertensive effect of Androgens
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may have an increased hypotensive effect when combined with antihypertensive agents
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may increase the levels of serum concentration of amphetamines
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
may have an increased neuromuscular-blocking effect when combined with neuromuscular-blocking agents
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may have an increased hypotensive effect when combined with antipsychotic agents
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may have an increased bradycardic effect when combined with other antihypertensive drugs
may increase the levels of serum concentration
may increase the levels of serum concentration
They may increase the hypotensive effect when combined with antihypertensive agents
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may have an increased QTc-prolonging effect when combined with QT-prolonging agents
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may enhance the hyperkalemic effect
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
may decrease the antihypertensive effect when combined with antihypertensive agents
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
it may enhance the QTc-prolonging effect of levoketoconazole
alfuzosin may enhance the hypotensive effect of Blood Pressure Lowering Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
antihypertensive drugs may enhance the hypotensive effect of antipsychotic Agents
fingolimod may enhance the QTc-prolonging effect of QT-prolonging Agents
fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the QTc-prolonging effect of Moxifloxacin
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
may enhance the QTc-prolonging effect of QT-prolonging Miscellaneous Agents
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
QT-prolonging Miscellaneous Agents may enhance the QTc-prolonging effect of anti-arrhythmics
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
NSAIDs May diminish the anti-hypertensive effect of Beta-Blockers
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
may enhance the hypotensive effect of Blood Pressure Lowering Agents
